🔎 Trials Near Me

Beranda › Limfoma Sel-T › North Carolina

Uji klinis Limfoma Sel-T di North Carolina

6 studi untuk Limfoma Sel-T mencari peserta di lokasi di North Carolina.

Kota di North Carolina

Teks studi resmi (Bahasa Inggris)

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Wake Forest University Health Sciences, Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • North Carolina Cancer Hospital, Chapel Hill
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06561048

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Novant Health Presbyterian Medical Center, Charlotte
  • dan 15 lainnya
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06724237

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Menerima pesertaFase 2
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06390319

MB-105 in Patients With CD5 Positive T-cell Lymphoma

  • University of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Okt 2025 · NCT06534060

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Carolina-Levine Children's Hospital, Charlotte
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.